Core Viewpoint - A class action lawsuit has been filed against Avantor, Inc. for alleged violations of federal securities laws during the period from March 5, 2024, to October 28, 2025, seeking to recover losses for investors [1][3]. Company Performance - Avantor reported weaker-than-expected organic sales in its Laboratory Solutions segment on April 25, 2025, and reduced its 2025 outlook, with the CFO acknowledging increased competitive intensity leading to lower volumes at certain customers. This resulted in a stock price decline of over 16% [4]. - On August 1, 2025, Avantor announced disappointing second quarter results and further reduced its full-year guidance, indicating ongoing competitive pressures, which led to a stock price drop of more than 15% [5]. - On October 29, 2025, Avantor disclosed weak third quarter financial results, including a 5% decline in organic revenue, contradicting previous management assurances of an improving trajectory. Following this announcement, the stock price fell by more than 23% [6]. Allegations in the Lawsuit - The lawsuit alleges that Avantor and certain senior executives made false and misleading statements and failed to disclose the true state of the company's competitive position in key product lines, particularly in Laboratory Solutions, which was weaker than represented. It also claims that Avantor was negatively impacted by increased competition, adversely affecting volumes, sales, and growth [8].

https://www.rgrdlaw.com/cases-avantor-inc-class-action-lawsuit-avtr.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at [email protected]. Lead plaintiff motions for the Avantor class action lawsuit must be filed with the court no later than December 29, 2025. CASE ALLEGATIONS: Avantor engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advance ...

Core Viewpoint - The Avantor class action lawsuit alleges that the company and its executives misrepresented the competitive positioning and financial health of Avantor, leading to significant stock price declines following disappointing financial results [3][4][5][6]. Group 1: Lawsuit Details - The lawsuit is titled "Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc." and seeks to represent purchasers of Avantor common stock, alleging violations of the Securities Exchange Act of 1934 [1]. - The lawsuit claims that Avantor's competitive positioning was weaker than publicly represented, and the company faced negative impacts from increased competition [3]. - The lead plaintiff motions must be filed by December 29, 2025, for those who suffered substantial losses [2]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported weak first-quarter results, leading to a more than 16% drop in share price after the CFO acknowledged the impact of increased competition [4]. - On August 1, 2025, the company reported disappointing second-quarter results and reduced its full-year guidance, resulting in a more than 15% decline in share price [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, causing a more than 23% drop in share price [6]. Group 3: Company Background - Avantor provides mission-critical products and services across various sectors, including biopharma, healthcare, and advanced technologies [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its significant recoveries in securities fraud cases, having recovered over $2.5 billion for investors in 2024 alone [8].

Core Viewpoint - Avantor, Inc. is facing a class action lawsuit due to allegations of failing to disclose its weakened competitive position and the negative impact of increased competition during the class period from March 5, 2024, to October 8, 2025 [1][3]. Summary by Sections Class Action Details - The class action lawsuit is on behalf of investors who purchased Avantor securities during the specified class period [1]. - Investors have until December 29, 2025, to file a lead plaintiff motion [1][2]. Allegations Against Avantor - The lawsuit claims that Avantor did not disclose its weaker competitive positioning and the adverse effects of heightened competition [3]. - On April 25, 2025, Avantor reported weak first-quarter financial results, citing reduced volumes due to increased competitive intensity, leading to a share price drop of over 16% [4]. - On August 1, 2025, the company reported disappointing second-quarter results and lowered its full-year guidance, with a share price decline of more than 15% attributed to the same competitive pressures [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, resulting in a share price drop of over 23% [6].

Core Viewpoint - The Avantor class action lawsuit alleges that the company and certain executives misrepresented the competitive positioning and financial health of Avantor, leading to significant stock price declines following disappointing financial results [3][4][5][6]. Group 1: Lawsuit Details - The lawsuit is titled "Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc." and seeks to represent purchasers of Avantor common stock, alleging violations of the Securities Exchange Act of 1934 [1]. - The lead plaintiff motions must be filed by December 29, 2025, for investors who suffered substantial losses [2][7]. Group 2: Allegations of Misrepresentation - The lawsuit claims that Avantor's competitive positioning was weaker than publicly represented, and the company faced negative impacts from increased competition [3]. - On April 25, 2025, Avantor reported weak first-quarter results, leading to a more than 16% drop in share price, as the CFO acknowledged the impact of increased competitive intensity [4]. - On August 1, 2025, the company reported disappointing second-quarter results and reduced its full-year guidance, resulting in a more than 15% decline in share price [5]. - On October 29, 2025, Avantor announced weak third-quarter results, including a 5% decrease in organic revenue growth, causing a more than 23% drop in share price [6]. Group 3: Company Background - Avantor provides mission-critical products and services across various sectors, including biopharma, healthcare, education, and advanced technologies [3].

Core Insights - Avantor, Inc. reported a revenue of $1.62 billion for the quarter ended September 2025, reflecting a decline of 5.3% year-over-year and a surprise of -1.56% compared to the Zacks Consensus Estimate of $1.65 billion [1] - The earnings per share (EPS) for the quarter was $0.22, down from $0.26 in the same quarter last year, with an EPS surprise of -4.35% against the consensus estimate of $0.23 [1] Revenue Performance - Bioscience Production revenue was $527.3 million, slightly below the average estimate of $536.7 million, representing a year-over-year decline of 2.9% [4] - Laboratory Solutions revenue totaled $1.1 billion, compared to the average estimate of $1.11 billion, marking a year-over-year decrease of 6.4% [4] Operating Income - Adjusted Operating Income for Laboratory Solutions was reported at $123.6 million, below the average estimate of $134.01 million [4] - Adjusted Operating Income for Corporate was -$14 million, better than the average estimate of -$19.3 million [4] - Adjusted Operating Income for Bioscience Production was $127.7 million, compared to the average estimate of $134.34 million [4] Stock Performance - Avantor's shares have returned +20.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Q3 2025 Earnings Earnings Presentation October 29, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking ...

Core Viewpoint - Avantor Inc. reported worse-than-expected second-quarter 2025 adjusted EPS, leading to a decline in stock price, with shares nearing their 52-week low [1]. Financial Performance - The company reported adjusted EPS of 24 cents, slightly below the consensus estimate of 25 cents [1]. - Sales for the quarter were $1.68 billion, nearly in line with the consensus of $1.675 billion, but fell 1% compared to the second quarter of 2024 [1][2]. - Net income decreased to $64.7 million from $92.9 million a year ago, while adjusted net income was $161.2 million compared to $168 million [5]. - Adjusted EBITDA was $279.8 million, down from $305.6 million, with a margin of 16.6% [5]. - Adjusted operating income fell from $277.2 million to $252.2 million, with a margin of 15.0% [6]. Segment Performance - Laboratory Solutions sales were $1.12 billion, a reported decrease of 3%, with a 1% organic decline [2]. - Bioscience Production sales were $561.3 million, also a reported decrease of 3%, but showed a 2% increase on an organic basis [3]. - The bioprocessing performance did not meet expectations due to planned maintenance at a manufacturing facility, despite strong demand for the monoclonal antibody platform [4]. Strategic Developments - The company announced significant actions to accelerate growth and enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027 [6]. - A five-year contract extension with BIO Business Solutions was executed, positioning the company to benefit from future funding levels in the biotech industry [7]. Market Position - Avantor stock trades at approximately 10.8 times the 2025 EBITDA estimate, compared to peers at 15.4 times and its own average of 15.9 times as a public company [8]. - The company's growth and margin profile are considered below peer levels, justifying the current discount to peers [8].

Core Insights - Avantor, Inc. reported revenue of $1.68 billion for the quarter ended June 2025, reflecting a decrease of 1.1% year-over-year, with EPS at $0.24 compared to $0.25 in the same quarter last year [1] - The reported revenue met the Zacks Consensus Estimate, showing a surprise of +0.38%, while the EPS fell short of expectations by 4% [1] Revenue Breakdown - Bioscience Production revenue was $561.3 million, slightly below the estimated $568.43 million, marking a year-over-year increase of +2.6% [4] - Laboratory Solutions revenue reached $1.12 billion, exceeding the average estimate of $1.11 billion, but represented a year-over-year decline of -2.9% [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was reported at $133.3 million, below the average estimate of $144.2 million [4] - Adjusted Operating Income for Corporate was -$20.8 million, worse than the average estimate of -$17.99 million [4] - Adjusted Operating Income for Bioscience Production was $139.7 million, slightly above the estimated $134.75 million [4] Stock Performance - Avantor's shares have returned -3.2% over the past month, contrasting with the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]